INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 11, Issue 2- 2024

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.02.004

The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]
[1]Department of Medical Laboratory Science, Kampala International University, Uganda.
[2]School of Nursing Science, Kampala International University, Uganda.
*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda,
emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Human Immunodeficiency Virus (HIV)-induced anemia remains a significant hematological complication, contributing to morbidity and complicating the management of individuals living with HIV. Erythropoietin (EPO), a key regulator of erythropoiesis, plays a central role in maintaining red blood cell homeostasis. This review explores the intricate relationship between EPO and HIV-induced anemia, shedding light on the multifaceted mechanisms influencing erythropoiesis in the context of HIV infection. The interplay between viral dynamics, immune activation, and the hematopoietic system is examined, offering insights into the challenges and potential therapeutic avenues for managing anemia in the HIV population. Keywords: Erythropoietin, HIV, Anemia, Hematopoiesis, Immune Activation, Therapeutics.

Keywords: Erythropoietin, HIV, Anemia, Pathophysiology, Therapeutic Strategies, Hematopoiesis, Immune Activation

Introduction

HIV infection remains a global health challenge, affecting millions of individuals worldwide. While advances in antiretroviral therapy (ART) have significantly improved the prognosis and quality of life for people living with HIV, hematological complications, particularly anemia, continue to pose substantial clinical challenges. Among the various factors contributing to HIV-induced anemia, the intricate relationship with erythropoietin (EPO), the primary hormone orchestrating erythropoiesis, remains a subject of significant interest.[1-18]

Anemia is a common complication in individuals living with HIV, with prevalence rates varying across populations and disease stages. The significance of anemia extends beyond its direct impact on red blood cell counts, influencing disease progression, overall health, and the efficacy of antiretroviral treatments. EPO, traditionally known for its role in stimulating red blood cell production in response to hypoxia, plays a central role in maintaining erythrocyte homeostasis. The regulation of EPO involves intricate interactions between the kidneys, liver, and bone marrow, ensuring a dynamic response to changing oxygen demands. Anemia in the context of HIV infection is multifactorial, involving both direct and indirect mechanisms. Direct viral effects, immune activation, opportunistic infections, and medication-related side effects contribute to the complex etiology of anemia in individuals with HIV.[19-38] Despite the recognized association between HIV and anemia, the specific role of EPO in this context remains less understood. This review aims to unravel the intricate relationship between HIV-induced anemia and EPO, exploring the underlying mechanisms and potential implications for therapeutic interventions.[39-44]

Pathophysiology of HIV-Induced Anemia

Human Immunodeficiency Virus (HIV) infection remains a global health challenge, affecting millions of individuals worldwide. Beyond its well-known impact on the immune system, HIV is associated with various hematological complications, with anemia standing out as a prevalent and clinically significant concern. The multifaceted etiology of anemia in the context of HIV involves complex interactions between the virus, immune responses, and hematopoietic processes. One key player in this intricate relationship is erythropoietin (EPO), the primary hormone orchestrating red blood cell production. Understanding the pathophysiology of HIV-induced anemia and the role of EPO is essential for developing targeted therapeutic strategies. HIV has a direct impact on hematopoietic progenitor cells within the bone marrow, leading to suppression of erythropoiesis. Viral proteins and factors released during the course of infection contribute to the inhibition of normal red blood cell production.[45-62]

Altered EPO receptor signaling in hematopoietic cells, induced by HIV, leads to decreased responsiveness to EPO. This reduction in EPO sensitivity further impedes the compensatory erythropoietic response to anemia. Persistent immune activation in HIV infection, characterized by elevated levels of proinflammatory cytokines, negatively impacts erythropoiesis. Inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) disrupt erythroid progenitor cell maturation. Chronic inflammation contributes to bone marrow dysfunction, affecting the microenvironment necessary for normal erythropoiesis. Disruption of the bone marrow niche further hinders the production of mature red blood cells. HIV-associated hemolytic anemia results from the direct infection of red blood cells, leading to their premature destruction. The release of free hemoglobin during hemolysis further contributes to oxidative stress and inflammation.[63-72]

HIV-induced inflammation triggers hepcidin production, leading to iron sequestration within macrophages. Functional iron deficiency ensues, limiting iron availability for erythropoiesis despite normal or elevated total body iron stores. Coinfections such as mycobacterial or parasitic infections common in HIV patients exacerbate anemia by additional mechanisms. Opportunistic infections may directly affect erythropoiesis or contribute to nutritional deficiencies. Certain antiretroviral medications, while crucial for managing HIV, may have hematologic side effects contributing to anemia. Awareness of drug-induced anemia is essential for optimizing treatment strategies.[73-82]

The EPO Response in HIV-Induced Anemia

Erythropoietin (EPO), a glycoprotein hormone produced primarily by the kidneys, plays a central role in regulating red blood cell production. In the context of HIV-induced anemia, the interplay between the virus, immune activation, and the

hematopoietic system significantly influences the EPO response. HIV-related nephropathy and coexisting renal complications can compromise the production of EPO by the kidneys. Renal impairment contributes to decreased EPO synthesis, impairing the compensatory response to anemia. Chronic immune activation and inflammation in HIV can directly suppress EPO production. Elevated levels of proinflammatory cytokines, including interleukin-6 (IL-6) and TNF-α, negatively impact the synthesis and release of EPO. HIV-induced alterations in erythroid progenitor cells can disrupt EPO receptor signaling pathways. Reduced EPO sensitivity hampers the ability of erythroid precursors to respond adequately to EPO stimulation.[83-88]

Viral proteins released during HIV infection may directly interfere with EPO signaling pathways, contributing to EPO resistance. The impaired response to EPO further exacerbates anemia by limiting the effectiveness of erythropoiesis. Elevated levels of inflammatory cytokines associated with HIV, such as IL-6 and IFN-γ, contribute to EPO resistance. These cytokines interfere with EPO signaling at multiple levels, diminishing its erythropoietic effects. Chronic inflammation disrupts the bone marrow microenvironment crucial for erythropoiesis. The inflammatory milieu contributes to impaired maturation of erythroid progenitors, further compromising the EPO response. HIV-associated hemolysis, a consequence of direct viral effects on red blood cells, influences the dynamics of the EPO response. The compensatory increase in EPO production aims to counteract the loss of red blood cells, but this response may be inadequate due to concurrent factors. Hemolytic stress in HIV-induced anemia poses challenges to the regulation of EPO production. The intricate balance between EPO synthesis, sensitivity, and the degree of hemolysis determines the effectiveness of the erythropoietic response.EPO replacement therapy has been explored as a potential intervention for HIV-induced anemia. However, the effectiveness of exogenous EPO may be limited by impaired EPO receptor signaling and other factors influencing EPO responsiveness. Targeting the underlying causes of impaired EPO response, such as inflammation and viral effects, is crucial for effective management. Antiretroviral therapy and strategies to mitigate inflammation may indirectly enhance the EPO response.[89]

Therapeutic Strategies

The erythropoietin (EPO) response in HIV-induced anemia is a dynamic process influenced by the intricate interplay between the virus, immune activation, and hematopoietic dysfunction. While EPO is the primary hormone regulating erythropoiesis, its efficacy can be compromised in the context of HIV infection. HIV has been associated with direct suppression of EPO production within the kidneys, the primary site of EPO synthesis. Viral factors and chronic inflammation contribute to renal dysfunction, limiting the kidneys' ability to respond adequately to anemia. Higher viral loads in HIV infection correlate with greater inhibition of EPO synthesis. Elevated HIV RNA levels directly interfere with the kidneys' ability to produce sufficient EPO, exacerbating anemia.[90] HIV-induced alterations in EPO receptor signaling on erythroid progenitor cells lead to reduced responsiveness to EPO stimulation.[91] Impaired intracellular signaling pathways contribute to ineffective erythropoiesis and an inadequate compensatory response to anemia. Proinflammatory cytokines, elevated in HIV infection, negatively impact EPO responsiveness. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) disrupt the EPO signaling cascade, further hampering erythropoietic activity. Chronic inflammation in HIV induces hepcidin production, leading to increased iron sequestration within macrophages. Elevated hepcidin levels contribute to functional iron deficiency, limiting iron availability for effective erythropoiesis. Dysregulation of iron metabolism, characterized by altered absorption and sequestration, compromises the effectiveness of exogenous EPO supplementation. Ensuring adequate iron availability becomes crucial for optimizing the response to EPO therapy.

Tailor exogenous EPO supplementation based on individual patient characteristics, including the severity of anemia, viral load, and response to therapy.[92] Adjust dosages to achieve optimal hematologic parameters while minimizing potential side effects. Administer concurrent iron supplementation to address potential functional iron deficiency and enhance the efficacy of exogenous EPO. Regular monitoring of iron status is crucial to prevent iron overload or deficiency. Choose antiretroviral medications with favorable hematologic profiles to mitigate potential drug-induced anemia. Regularly monitor hematologic parameters during ART and adjust treatment regimens as needed. Achieving viral suppression through effective ART can contribute to immune reconstitution and may positively impact EPO responsiveness. Evaluate the potential synergistic effects of immune reconstitution and EPO therapy on erythropoiesis. Aggressively manage and treat opportunistic infections that contribute to anemia. Early detection and treatment of coinfections can alleviate the burden on erythropoiesis. Provide nutritional support to address deficiencies and promote overall health. Collaboration with nutritionists ensures a comprehensive approach to managing anemia. Support research endeavors focused on developing novel therapeutic approaches for HIV-induced anemia. Explore potential interventions targeting the underlying mechanisms of impaired EPO responsiveness. Encourage participation in clinical trials investigating new treatment modalities for anemia in individuals with HIV. Collaborate with researchers and pharmaceutical companies to advance therapeutic options.

Conclusion

The intricate relationship between erythropoietin (EPO) and HIV-induced anemia underscores the complexity of managing hematological complications in individuals living with HIV. As explored in this review, the pathophysiology of HIV-induced anemia involves a multifaceted interplay between the virus, immune responses, and erythropoietic processes. HIV exerts direct effects on hematopoietic progenitor cells, leading to impaired responsiveness to erythropoietin. Viral-induced alterations in EPO signaling pathways contribute to the inadequate compensatory response to anemia. Chronic immune activation and inflammation in HIV infection disrupt the normal regulatory mechanisms of EPO production. The dysfunctional bone marrow microenvironment further complicates the ability of EPO to stimulate efficient erythropoiesis.

EPO supplementation has been explored as a therapeutic approach to mitigate anemia in individuals with HIV. Challenges include the risk of viral replication stimulation and concerns about potential adverse effects. Addressing chronic inflammation through antiretroviral therapy (ART) and anti-inflammatory agents may indirectly improve EPO responsiveness. Controlling opportunistic infections and managing comorbidities contribute to an overall reduction in inflammation. The choice of antiretroviral medications can impact the hematologic profile, and selecting drugs with a favorable side effect profile is essential. Regular monitoring for drug-induced anemia and appropriate adjustments in treatment regimens are crucial. Effective management of coinfections, including mycobacterial and parasitic infections, is integral to improving anemia in HIV patients. A holistic approach considers the broader infectious disease context and nutritional status.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.

3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2.links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129.links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471.links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
14. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
15. Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.
16. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
17. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.

18. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.
19. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
20. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
21. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
22. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
23. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130.links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
24. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
25. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
26. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
27. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
28. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
29. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life

in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.

30. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
31. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
32. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
33. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
34. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-4.
35. Obeagu EI. Erythrocyte enumeration and serum erythropoietin in chronic kidney disease patients: A study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences. 2016;3(7):163-70.
36. Ifeanyi OE. A review on erythropoietin. Int J Adv Res Biol Sci. 2015;2(4):35-47.
37. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
38. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4.
39. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
40. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
41. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
42. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
43. Obeagu EI, Obeagu GU, Amilo GI. Haematological changes in patients of chronic kidney disease in Umuahia, Abia

State, Nigeria. Curr Trends Biomed Eng Biosci. 2018; 11:34-7.
44. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-8.
45. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14.http://ajdhs.com/index.php/journal/article/view/39.
46. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI:**DOI:** 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
47. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
48. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211.http://research.sdpublishers.net/id/eprint/2819/.
49. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
50. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
51. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
52. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
53. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE.European Journal of Pharmaceutical and Medical Research, 2023;10(8): 564-568
54. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY.World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.

links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
55. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
56. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
57. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
58. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
59. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
60. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. EC Emergency Medicine and Critical Care. 2020;4(7):33-40.
61. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
62. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
63. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
64. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
65. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
66. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
67. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.

68. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
69. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
70. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
71. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
72. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
73. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
74. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
75. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
76. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood TransfusDisord. 2018;1(2).
77. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
78. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
79. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
80. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
81. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
82. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi:

10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
83. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
84. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
85. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
86. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
87. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
88. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
89. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
90. Gocht D. *Expression and function of erythropoietin and its receptor in invertebrate nervous systems* (Doctoral dissertation, Göttingen, Univ., Diss., 2009).
91. Deshet-Unger N, Kolomansky A, Ben-Califa N, Hiram-Bab S, Gilboa D, Liron T, Ibrahim M, Awida Z, Gorodov A, Oster HS, Mittelman M. Erythropoietin receptor in B cells plays a role in bone remodeling in mice. Theranostics. 2020;10(19):8744.
92. Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, Barbieri E, Emili R. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients. 2021;13(2):482.

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Medical Sciences
DOI: 10.22192/ijcrcps.2024.11.02.004	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 11(2): 30-40.
DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.02.004

